Abstract
Currently, statins are in lime light due to their pleiotropic effects. One of their pleiotropic effects is on glucose metabolism. Various clinical and preclinical studies were designed to evaluate statins effect on glucose metabolism. This review describes preclinical and clinical evidences of statins action on glucose metabolism.
Keywords: Statin, diabetes, insulin resistance, glucose metabolism, solubility
Mini-Reviews in Medicinal Chemistry
Title: Can Statin be a Novel Pharmacophore for Antidiabetic Activity?
Volume: 9 Issue: 12
Author(s): S. A. Parmar and A. A. Mehta
Affiliation:
Keywords: Statin, diabetes, insulin resistance, glucose metabolism, solubility
Abstract: Currently, statins are in lime light due to their pleiotropic effects. One of their pleiotropic effects is on glucose metabolism. Various clinical and preclinical studies were designed to evaluate statins effect on glucose metabolism. This review describes preclinical and clinical evidences of statins action on glucose metabolism.
Export Options
About this article
Cite this article as:
Parmar A. S. and Mehta A. A., Can Statin be a Novel Pharmacophore for Antidiabetic Activity?, Mini-Reviews in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/1389557789957340
DOI https://dx.doi.org/10.2174/1389557789957340 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Improving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
Current Pharmaceutical Design Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Current Pharmaceutical Design